MitchellBrianLowensteinMD
Rheumatology • Palm Harbor, FLAssistant Clinical Professor, Rheumatology, University of South Florida College of Medicine
Dr. Lowenstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
32615 Us Highway 19 N
Ste 2
Palm Harbor, FL 34684Phone+1 727-789-2784Fax+1 727-785-3537
Education & Training
Uconn School Of MedicineClass of 1978- University of ConnecticutFellowship, Rheumatology, 1975 - 1977
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 1972 - 1975
Certifications & Licensure
FL State Medical License 1977 - 2026
CO State Medical License 2018 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Medisoft Clinical EHR, McKesson Corporation, 2012-2013
- Top Doctors: Florida Castle Connolly, 2000
- Fellow American College of Rheumatology
Clinical Trials
- A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor Start of enrollment: 2013 Jul 01
- An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2013 Jun 27
- A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus Start of enrollment: 2014 Jan 01
Publications & Presentations
PubMed
- 26 citationsA pilot study of rituximab in immune-mediated inner ear disease.Stanley Cohen, Peter S. Roland, Angela G. Shoup, Mitchell Lowenstein, Herbert Silverstein
Audiology & Neuro-Otology. 2011-01-01 - 559 citationsComparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION studyGraeme Jones, Anthony Sebba, Jieruo Gu, Mitchell B. Lowenstein, Armando Calvo
Annals of the Rheumatic Diseases. 2010-01-01 - 152 citationsOcrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, d...Mark C. Genovese, Jeffrey L. Kaine, Mitchell B. Lowenstein, Jose Del Giudice, Andrew R. Baldassare
Arthritis and Rheumatism. 2008-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
